GSK (GSK) stock is in focus as the U.S. FDA expands authorization for the company's Arexvy RSV vaccine to cover adults 18–49. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results